Overview / Abstract: |
In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now. STATEMENT OF NEED Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphoplasmacytic bone marrow infiltration and the presenceof serum monoclonal immunoglobulin M (IgM) (LLS, 2021). Often considered a disease occurring in older adults, this malignancy accounts for between 1% and 2% of non-Hodgkin lymphomas (Dimopoulos & Kastritis, 2019; ACS, 2018). Whereas patients with low- and intermediate-risk disease have 5-year survival rates of 87% and 68%, respectively, those with high-risk disease have a 5-year survival rate of only 36% (ACS, 2018). Waldenstrom macroglobulinemia is a disease that requires keeping up to date on the knowledge of risk stratification systems, efficacy and safety data for novel therapeutic approaches, and surveillance and management strategies for adverse events associated with novel treatments (i3 Health, 2021). In this activity, Morie Gertz, MD, MACP, will update providers on the latest evidence-based treatment and management plans for patients with WM. TARGET AUDIENCE Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies. LEARNING OBJECTIVES Discuss predictive and prognostic markers that can individualize treatment selection for patients with WM |
Expiration |
Feb 14, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 CME | 1.0 NCPD | 1.0 CPE | MOC | ILNA |
Accreditation |
ACCME, ANCC, ACPE, ONCC |
Presenters / Authors / Faculty |
Morie Gertz, MD, MACP |
Activity Specialities / Related Topics |
Hematology, Oncology / Cancer / Radiation Therapy, Pharmacology |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from BeiGene, Bristol Myers Squibb, Merck, and Seagen. |
Keywords / Search Terms |
i3 Health i3health, hematologyy, Waldenstrom macroglobulinemia, WM, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD, CME ,Free CE CME, Free CE CME, ANCC Free CE CME Free CE CME Free CE CME Free CE CME |